AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform.

AstraZeneca announced four research collaborations to utilise CRISPR across its entire discovery platform in key therapeutic areas. The technology will be used to identify and validate new drug targets in preclinical models that closely resemble human diseases. AstraZeneca will share cell lines and compounds with its partners, working with them to publish significant findings to contribute to scientific progress in the field. These collaborations will complement AstraZeneca’s existing CRISPR programme and build on their ‘open innovation’ approach to research and development.

Dr. Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development, AstraZeneca, said: “CRISPR is a simple yet powerful tool that enables us to manipulate genes of potential importance in disease pathways and examine the impact of these modifications in a highly precise way. By combining the great science from our labs with these world-renowned academic and industry partners, we will be able to integrate this ground-breaking technology into our research and help accelerate the discovery of novel treatments for patients.”

AstraZeneca will be collaborating with The Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Broad Institute/Whitehead Institute, and Thermo Fisher Scientific.

For the full press release and details of each collaboration click here.

For a video on CRISPR technology for genome editing click here.

 

More on these topics